Circle Cardiovascular Imaging

Circle Cardiovascular Imaging Inc. stands as a significant entity in the global cardiac imaging software market, having been acquired by Thoma Bravo in February 2022. Founded in 2007 by Greg Ogrodnick and Matthias Friedrich in Calgary, Alberta, the company has established a considerable footprint in the healthcare technology sector. The foundation of the company is rooted in the founders' expertise; Ogrodnick brought a background in business and commercialization, while Dr. Friedrich contributed his extensive experience as a cardiologist and researcher in cardiac MRI. This combination of commercial acumen and deep clinical knowledge has been a core driver of the company's trajectory.

The firm's primary business involves the development and provision of AI-powered software solutions for cardiovascular imaging. Circle CVI serves a global client base that includes hospitals, clinics, and imaging centers across more than 90 countries. Its business model centers on licensing its flagship software platform, cvi42, to these healthcare providers. Revenue is generated through software sales, subscriptions, and potentially support and maintenance contracts, enabling physicians to better diagnose and manage cardiovascular diseases. The acquisition by Thoma Bravo, a leading software investment firm, marked a significant milestone, providing Circle CVI with substantial resources to accelerate its growth, expand its product portfolio, and enhance its market penetration.

The core product, cvi42, is a multi-modality software platform designed for the reading and reporting of cardiac imaging studies. It supports various imaging techniques, including Cardiac MR (CMR), Cardiac CT, and interventional planning. The platform integrates artificial intelligence to automate and standardize the analysis of cardiac images, which allows for accurate quantification of heart function and the identification of complex cardiovascular conditions. Key features include tools for 4D/3D visualization, detailed blood flow analysis (4D flow), and modules for electrophysiology (EP) planning. By providing physicians with precise and reproducible measurements, cvi42 aims to improve diagnostic accuracy, streamline clinical workflows, and ultimately enhance patient outcomes while optimizing the use of healthcare resources.

Keywords: cardiac imaging, medical software, AI diagnostics, cardiovascular health, Thoma Bravo, cvi42, medical technology, diagnostic software, healthcare IT, cardiology